DARE (Dare Bioscience, Inc. Common Stock) Stock Analysis - AI Report

Dare Bioscience, Inc. Common Stock (DARE) is a publicly traded Healthcare sector company. As of May 21, 2026, DARE trades at $2.34 with a market cap of $31.61M and a P/E ratio of -2.46. DARE moved +5.11% today. Year to date, DARE is +17.09%; over the trailing twelve months it is -19.38%. Its 52-week range spans $1.27 to $9.19. Analyst consensus is buy with an average price target of $10.00. Rallies surfaces DARE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What is the AI research view on DARE?

Rallies AI research for DARE combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.

DARE Key Metrics

Key financial metrics for DARE
MetricValue
Price$2.34
Market Cap$31.61M
P/E Ratio-2.46
EPS$-0.96
Dividend Yield0.00%
52-Week High$9.19
52-Week Low$1.27
Volume540
Avg Volume0
Revenue (TTM)$1.16M
Net Income$-12.02M
Gross Margin0.00%

Latest DARE News

DARE Analyst Consensus

2 analysts cover DARE: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $10.00.

Common questions about DARE

What is the AI research view on DARE?
Rallies AI research for DARE combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
What data powers the Rallies AI report for DARE?
Rallies AI research for DARE combines live market data, financials, news, analyst context, hedge fund ownership, politician disclosures, insider activity, and risk factors.
Is DARE research on Rallies investment advice?
No. Rallies provides research, data, and educational context for DARE. It does not provide personalized investment advice.
DARE

DARE